“The unique fusion of individual innovative technologies will provide a novel diagnostic tool leading to a better understanding of the underlying pathophysiology of rare anaemia.”

Lars Kaestner, Coordinator of CoMMiTMenT

Proof-of-concept

With the proposed novel methodology (µCOSMOS), CoMMiTMenT will identify and characterise the molecular causes of RBC channelopathies and channel-linked disorders and propose personalised pharmacological interventions to counteract the abnormal function of ion transporters. This bench-to-bedside approach will be verified by an accompanying proof-of-concept test. CoMMiTMenT will have access to a phase II clinical study of patients with sickle cell disease (performed and funded outside of CoMMiTMenT), in which the concept of a personalized dose (not a personalized "Cocktail" of drugs) can be tested. With respect to sickle cell disease, it is possible that the transition into clinical application will be reached within CoMMiTMenT.